Lyell Immunopharma (LYEL) Free Cash Flow (2020 - 2026)
Lyell Immunopharma (LYEL) reported Free Cash Flow of -$38.6 million for Q1 2026, up 29.68% on a YoY basis from -$29.8 million in Q1 2025, and down 16.86% sequentially from -$33.0 million in Q4 2025.
Lyell Immunopharma (LYEL) Free Cash Flow (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of Free Cash Flow data on file, last reported at -$38.6 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 29.68% year-over-year to -$38.6 million; the trailing twelve-month figure through Mar 2026 stood at -$134.5 million (up 23.31% YoY), and the FY2025 full-year result was -$150.8 million, up 7.22% from the prior year.
- Free Cash Flow declined to -$38.6 million in Q1 2026, from -$33.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$21.9 million in Q4 2022 to a low of -$54.9 million in Q1 2025.
- A 5-year average of -$40.5 million and a median of -$40.1 million in 2023 frame the typical range for Free Cash Flow.
- Peak annual rise in Free Cash Flow reached 76.53% in 2022, while the deepest fall reached 118.71% in 2022.
- Tracing LYEL's Free Cash Flow over 5 years: stood at -$21.9 million in 2022, then slumped by 97.82% to -$43.3 million in 2023, then decreased by 8.42% to -$47.0 million in 2024, then advanced by 29.67% to -$33.0 million in 2025, then slipped by 16.86% to -$38.6 million in 2026.
- Business Quant data shows LYEL's Free Cash Flow at -$38.6 million in Q1 2026, -$33.0 million in Q4 2025, and -$28.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.95 Mn |
| 10 | Lyell Immunopharma | 276.08 Mn | 276.08 Mn | - | -38.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.60 Mn |
| Mar 31, 2026 | -38.60 Mn |
| Dec 31, 2025 | -33.03 Mn |
| Dec 31, 2025 | -33.03 Mn |
| Sep 30, 2025 | -28.16 Mn |
| Sep 30, 2025 | -28.16 Mn |
| Jun 30, 2025 | -34.72 Mn |
| Jun 30, 2025 | -34.72 Mn |
| Mar 31, 2025 | -54.89 Mn |
| Mar 31, 2025 | -54.89 Mn |
| Dec 31, 2024 | -46.97 Mn |
| Dec 31, 2024 | -46.97 Mn |
| Sep 30, 2024 | -35.41 Mn |
| Sep 30, 2024 | -35.41 Mn |
| Jun 30, 2024 | -38.11 Mn |
| Jun 30, 2024 | -38.11 Mn |
| Mar 31, 2024 | -42.05 Mn |
| Mar 31, 2024 | -42.05 Mn |
| Dec 31, 2023 | -43.32 Mn |
| Dec 31, 2023 | -43.32 Mn |